We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Marceline Clementine Appointed Chief Financial Officer
News

Marceline Clementine Appointed Chief Financial Officer

Marceline Clementine Appointed Chief Financial Officer
News

Marceline Clementine Appointed Chief Financial Officer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Marceline Clementine Appointed Chief Financial Officer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Trophos SA has announced the appointment of Marceline Clementine as chief financial officer.

Marceline Clementine has more than 30 years experience in the world of finance. She joined Trophos in 2006 as administration and finance manager.

Before that, she had worked as chief accountant or financial controller at various companies in the real estate and catering sectors, including Groupe FLO.

She is now responsible for all administrative and financial services at Trophos, as well as for human resources management.

Marceline Clementine succeeds Christine Placet, the former chief financial officer, who has just been promoted to the post of chief executive officer of Trophos.

“We are delighted to welcome Marceline Clementine as chief financial officer,” said Christine Placet, the CEO of Trophos.

Placet continued, “This appointment is a recognition of Ms. Clementine’s competence in financial matters and her strong commitment to Trophos over the past few years. Her financial management skills are a precious asset for the company. We are continuing our quest to find strategic partners for our current programs to guarantee the future of our company, which was founded 13 years ago now.”

Trophos has sufficient funding in hand to continue its research activities up to 2014.

The company is currently undertaking several programs focused on the following drug candidates:
• Olesoxime in Spinal Muscular Atrophy (SMA): a pivotal study is underway and the results are expected in the second half of 2013.
• Olesoxime for multiple sclerosis (MS) disease progression: a phase II proof-of-concept study has been designed in conjunction with international MS specialists.
• TRO40303 cardiac protection compound: a phase IIa proof-of-concept study in cardiac ischemia-reperfusion injury (IRI) is underway and the results are expected in the first half of 2013.

Advertisement